A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine.

Trial Profile

A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Sponsors CoLucid Pharmaceuticals
  • Most Recent Events

    • 21 Jun 2012 Additional company (Eli Lilly) added in association as reported by European Clinical Trials Database.
    • 30 Aug 2011 Results were presented in a CoLucid Pharmaceuticals media release.
    • 09 Jun 2010 Primary endpoint 'Headache severity' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top